| S2765 |
MK-2048 |
MK-2048 is a potent inhibitor of integrase (IN) and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively. |
Selective |
Integrase, IC50: 2.6 nM; Integrase (R263K), IC50: 1.5 nM |
| S4642 |
Dolutegravir Sodium |
Dolutegravir Sodium (GSK-1349572A) is a HIV integrase inhibitor with IC50 of 2.7 nM. |
Selective |
HIV integrase, IC50: 2.7 nM |
| S2667 |
Dolutegravir |
Dolutegravir is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. |
Selective |
HIV integrase, IC50: 2.7 nM |
| S2005 |
Raltegravir |
Raltegravir is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. It shows greater than 1000-fold selectivity for HIV-1 IN over several related Mg2+-dependent enzyme such as HCV polymerase, HIV reverse transcriptase, HIV RNaseH and human α-, β-, γ-polymerases. |
Selective |
Integrase (WT PFV), IC50: 90 nM; Integrase (S217Q PFV), IC50: 40 nM |
| S4187 |
Salicylanilide |
Salicylanilides (WR10019,2-Hydroxybenzanilide) are a group of compounds with a wide range of biological activities including antiviral potency, antibacterial (including antimycobacterial) and antifungal activities. |
Selective |
|
| S5245 |
Raltegravir potassium |
Raltegravir Potassium(MK-0518 potassium) is the orally bioavailable potassium salt of raltegravir, the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor. |
Selective |
|
| S7766 |
Cabotegravir (GSK1265744) |
Cabotegravir (GSK744, GSK1265744, S/GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.
|
Selective |
|
